Heidenreich PA,Bozkurt B,Aguilar D,Allen LA,Byun JJ,Colvin MM .2022 .AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 79 : e263-421.
Shahim B,Kapelios CJ,Savarese G,Lund LH .2023 .Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev, 9 : e11.
Kesehatan Republik Indonesia Kementrian .2018 .. Laporan Nasional Riskesdas, : 182-3.
Fukuta H,Goto T,Wakami K,Ohte N. .2016 .Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Eur J Prev Cardiol, 23 : 78-85.
Lewis EF,Kim HY,Claggett B,Spertus J,Heitner JF,Assmann SF .2016 .Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ Heart Fail, 9 : e001937.
Stasch JP,Pacher P,Evgenov O V. P .2011 .Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 123 : 2263-73.
Armstrong PW,Roessig L,Patel MJ,Anstrom KJ,Butler J,Voors AA .2018 .Randomized, DoubleBlind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail, 6 : 96-104.
Armstrong PW,Pieske B,Anstrom KJ,Ezekowitz J,Hernandez AF,Butler J .2020 .Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Eng J Med, 382 : 1883-93.
Filippatos G,Maggioni AP,Lam CSP,Pieske-Kraigher E,Butler J,Spertus J .2017 .Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail, 19 : 782-91.
Gheorghiade M,Greene SJ,Butler J,Filippatos G,Lam CSP,Maggioni AP .2015 .Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction the socrates-reduced randomized trial. J Am Med Assoc, 314 : 2251-62.
Pieske B,Maggioni AP,Lam CSP,Pieske-Kraigher E,Filippatos G,Butler J .2017 .Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: Results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES- PRESERVED) study. Eur Heart J, 38 : 1119-27.
Higgins JPT .2011 .. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, : .
Dzhioeva O,Belyavskiy E .2020 .Diagnosis and management of patients with heart failure with preserved ejection fraction (Hfpef): Current perspectives and recommendations. Ther Clin Risk Manag, 16 : 769-85.
Lin Y,Wu M,Liao B,Pang X,Chen Q,Yuan J .2021 .Comparison of Pharmacological Treatment Effects on LongTime Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta- analysis of Randomized Controlled Trials. Front Pharmacol, 12 : 707777.
Li Q,Li Z,Li T,Wang Y,Feng J,Lu C .2021 .Efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Pharmazie, 76 : 488-93.
Coats AJS .2020 .Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?. Eur J Heart Fail, 22 : 576-7.
Aimo A,Pateras K,Stamatelopoulos K,Bayes-Genis A,Lombardi CM,Passino C .2021 .Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovasc Drugs Ther, 35 : 1067-76.
Aimo A,Castiglione V,Vergaro G,Panichella G,Senni M,Lombardi CM .2022 .The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev, 27 : 1165-71.
Tran BA,Serag-Bolos ES,Fernandez J,Miranda AC .2023 .Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. J Pharm Pract, 36 : 905-14.
Follmann M,Ackerstaff J,Redlich G,Wunder F,Lang D,Kern A .2017 .Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem, 60 : 5146-61.